221 related articles for article (PubMed ID: 10146941)
1. Simvastatin: a pharmacoeconomic evaluation of its cost-effectiveness in hypercholesterolaemia and prevention of coronary heart disease.
Chrisp P; Lewis NJ; Milne RJ
Pharmacoeconomics; 1992 Feb; 1(2):124-45. PubMed ID: 10146941
[TBL] [Abstract][Full Text] [Related]
2. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C.
Hamilton VH; Racicot FE; Zowall H; Coupal L; Grover SA
JAMA; 1995 Apr; 273(13):1032-8. PubMed ID: 7897787
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Plans-Rubió P
Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.
Johannesson M; Jönsson B; Kjekshus J; Olsson AG; Pedersen TR; Wedel H
N Engl J Med; 1997 Jan; 336(5):332-6. PubMed ID: 9011785
[TBL] [Abstract][Full Text] [Related]
5. Lipid-lowering for prevention of coronary heart disease: what policy now?
Ul Haq I; Ramsay LE; Pickin DM; Yeo WW; Jackson PR; Payne JN
Clin Sci (Lond); 1996 Oct; 91(4):399-413. PubMed ID: 8983865
[TBL] [Abstract][Full Text] [Related]
6. [Cost-effectiveness of lowering of blood cholesterol using simvastatin and cholestyramine].
Martens LL; Rutten FF; Kuijpens JL; Winter J
Ned Tijdschr Geneeskd; 1991 Apr; 135(15):655-9. PubMed ID: 1903849
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.
Martens LL; Guibert R
Clin Ther; 1994; 16(6):1052-62; discussion 1036. PubMed ID: 7697684
[TBL] [Abstract][Full Text] [Related]
8. Treating hyperlipidemia for the primary prevention of coronary disease. Are higher dosages of lovastatin cost-effective?
Perreault S; Hamilton VH; Lavoie F; Grover S
Arch Intern Med; 1998 Feb; 158(4):375-81. PubMed ID: 9487235
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease.
Goldman L; Weinstein MC; Goldman PA; Williams LW
JAMA; 1991 Mar; 265(9):1145-51. PubMed ID: 1899896
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
Hsu I; Spinler SA; Johnson NE
Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of drug therapy for hypercholesterolaemia: a review of the literature.
Thompson D; Oster G
Pharmacoeconomics; 1992 Jul; 2(1):34-42. PubMed ID: 10146977
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of simvastatin versus cholestyramine: results for Sweden.
Hjalte K; Lindgren B; Persson U
Pharmacoeconomics; 1992 Mar; 1(3):213-6. PubMed ID: 10147032
[TBL] [Abstract][Full Text] [Related]
13. Simvastatin. A reappraisal of its cost effectiveness in dyslipidaemia and coronary heart disease.
Goa KL; Barradell LB; McTavish D
Pharmacoeconomics; 1997 Jan; 11(1):89-110. PubMed ID: 10172918
[TBL] [Abstract][Full Text] [Related]
14. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal.
Pedersen TR; Tobert JA
Drug Saf; 1996 Jan; 14(1):11-24. PubMed ID: 8713485
[TBL] [Abstract][Full Text] [Related]
15. Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.
Cobos A; Jovell AJ; García-Altés A; García-Closas R; Serra-Majem L
Clin Ther; 1999 Nov; 21(11):1924-36. PubMed ID: 10890264
[TBL] [Abstract][Full Text] [Related]
16. An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).
Smith DG; McBurney CR
Pharmacoeconomics; 2003; 21 Suppl 1():13-23. PubMed ID: 12648031
[TBL] [Abstract][Full Text] [Related]
17. Clinical benefits and cost-effectiveness of lowering serum cholesterol levels: the case of simvastatin and cholestyramine in The Netherlands.
Martens LL; Rutten FF; Erkelens DW; Ascoop CA
Am J Cardiol; 1990 Mar; 65(12):27F-32F. PubMed ID: 2107736
[TBL] [Abstract][Full Text] [Related]
18. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.
Hilleman DE; Phillips JO; Mohiuddin SM; Ryschon KL; Pedersen CA
Clin Ther; 1999 Mar; 21(3):536-62. PubMed ID: 10321422
[TBL] [Abstract][Full Text] [Related]
19. [Effectiveness and tolerability of simvastatin in patients with moderate-to-severe hypercholesterolemia. Results of a 12-month study].
Ghizzoni G; Rusconi C; Faggiano P; Sabatini T; Oneglia C; Gardini A
Minerva Cardioangiol; 1993 Mar; 41(3):105-9. PubMed ID: 8510811
[TBL] [Abstract][Full Text] [Related]
20. Pharmaco-economic assessment of the HMG-CoA reductase inhibitors.
Smart AJ; Walters L
S Afr Med J; 1994 Dec; 84(12):834-7. PubMed ID: 7570232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
